COVID-19 is an infectious disease caused by the coronavirus known as SARS-CoV-2. Coronaviruses are a broad family of viruses that can cause infections in humans, birds and mammals. Sometimes they can be transmitted from animals to people.
To ensure a rapid response to future health emergencies in Europe, HIPRA is part of the EU FAB project of the European Commission as a strategic partner for the development and production of vaccines.
HIPRA is committed to providing solutions that contribute to improving the global health, of both people and animals.
More than 50 years focused on research, production and commercialization of highly innovative vaccines.
HIPRA has a singular model that controls all phases of vaccine creation: research, production and marketing.
HIPRA has a strong international presence with a marketing and sales team distributed over 40 subsidiaries worldwide, which ensure that more than 100 countries can benefit from the products.
A team of more than 2,400 persons, multicultural and multidisciplinary, that under the same values, works to offer the best solutions.
Putting all the enthusiasm, knowledge and talent, HIPRA is committed to continue innovating in solutions that have a positive impact on global health.
Discover our latest news